Combination chemotherapy with adriamycin (NSC-123127) and 1-(2-chloroethyl)-3-cyclohexyl 1-nitrosourea (CCNU; NSC-79037).
D000230:Adenocarcinoma / Q000188:drug therapy; D000328:Adult; D000368:Aged; D000970:Antineoplastic Agents / Q000009:adverse effects / Q000627:therapeutic use*; D001772:Blood Cell Count; D001853:Bone Marrow / Q000187:drug effects; D001943:Breast Neoplasms / Q000188:drug therapy; D002277:Carcinoma / Q000188:drug therapy*; D002294:Carcinoma, Squamous Cell / Q000188:drug therapy; D002986:Clinical Trials as Topic; D003510:Cyclohexanes / Q000009:adverse effects / Q000627:therapeutic use; D004317:Doxorubicin / Q000009:adverse effects / Q000627:therapeutic use*; D004359:Drug Therapy, Combination; D005260:Female; D006197:Hair / Q000187:drug effects; D006801:Humans; D008223:Lymphoma / Q000188:drug therapy; D008297:Male; D008545:Melanoma / Q000188:drug therapy; D008875:Middle Aged; D009362:Neoplasm Metastasis; D009369:Neoplasms / Q000188:drug therapy*; D009607:Nitrosourea Compounds / Q000009:adverse effects / Q000627:therapeutic use*
D000970:Antineoplastic Agents; D003510:Cyclohexanes; D009607:Nitrosourea Compounds; D004317:Doxorubicin